Compare Becton Dickinson and Co (BDX) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs IQIYI Inc - ADR — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while IQIYI Inc - ADR trades at $1.35 (market cap $1.31B). The key difference: Becton Dickinson and Co is far larger — about 37.4× IQIYI Inc - ADR's market cap, and Becton Dickinson and Co pays a 2.34% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| BDX | IQ | |
|---|---|---|
Market Cap | $48.93B | $1.31B |
Sector | Health | Media |
52-Week High | $185.39 | $2.79 |
52-Week Low | $138.62 | $0.96 |
Enterprise Value | $65.03B | $2.89B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
iQIYI (IQ) trades at $1.33, up 3.1% in 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 revenue of $915.2M, missing expectations, but beat EPS estimates. Valuation ratios show low P/S and P/B, but negative profitability metrics persist. Recent news highlights AI platform growth and leadership changes, with analyst consensus leaning buy.
Outlook: Potential upside exists from AI initiatives and cost controls, but risks include revenue declines, regulatory pressures, and negative cash flow projections. Investors should weigh low valuation against profitability challenges and China market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
